Novartis: Cystic Fibrosis trials
The registry lists 20 Cystic Fibrosis studies with Novartis as lead sponsor. 0 are open to participants now and 14 have results posted.
Phase 1 4Phase 2 3Phase 3 7Phase 4 6No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic FibrosisCompletedNCT02566044Phase 1/2Results posted
- Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.AeruginosaTerminatedNCT02248922Phase 4Results posted
- Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis PatientsTerminatedNCT02190604Phase 1/2Results posted
- Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis PatientsCompletedNCT02178540Phase 4Results posted
- Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off CyclesTerminatedNCT02015663Phase 4Results posted
- Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)CompletedNCT01844778Phase 4Results posted
- Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic FibrosisCompletedNCT01519661Phase 4Results posted
- Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 YearsCompletedNCT01082367Phase 3Results posted
- Second Open Label Extension to Bridging Study CTBM100C2303CompletedNCT01069705Phase 3Results posted
- Open Label Extension to Bridging Study CTBM100C2303CompletedNCT00982930Phase 3Results posted
- A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus PlaceboCompletedNCT00918957Phase 3Results posted
- An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)TerminatedNCT00787917Phase 4Results posted
- Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic FibrosisCompletedNCT00391976Phase 3Results posted
- Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic FibrosisCompletedNCT00388505Phase 3Results posted
- Assess Increased Mortality Risk With Each Year of Delayed Tobramycin Solution (TIS) Initiation, and Effect of TIS on Mortality Across Study CentersWithdrawnNCT01460849
- Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic FibrosisCompletedNCT01460836
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic FibrosisCompletedNCT00506792Phase 2
- Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic StudyCompletedNCT00420836Phase 1
- Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy StudyCompletedNCT00399945Phase 1
- Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis SubjectsTerminatedNCT00125346Phase 3